MétaCan
Menu
← Back to cohort
Record W4416141008 · doi:10.1093/neuonc/noaf201.0596

DNAR-05. Discovery and development of a novel CNS-penetrating ATR inhibitor

2025· article· en· W4416141008 on OpenAlexaff
Jeffrey Bacha, Sarah Truong, Beibei Zhai, Louise Ramos, Mona Marzban, Fariba Ghaidi, Marshall Drew-Brook, Mehran Khodabandeh, Sara Ibrahim Omar, Jason Rolfe, Seyed Ali Saberali, Xiaoqi Chen, Dennis Brown, John Langlands, Mads Daugaard

Bibliographic record

VenueNeuro-Oncology · 2025
Typearticle
Languageen
FieldMedicine
TopicPARP inhibition in cancer therapy
Canadian institutionsUniversity of British ColumbiaVariation Biotechnologies (Canada)
Fundersnot available
KeywordsDrug discoveryAdeptIn vivoKinaseCancer therapyMechanism (biology)Cancer

Abstract

fetched live from OpenAlex

Abstract Ataxia telangiectasia and Rad3-related protein serine/threonine kinase (ATR) is a key enzyme in the regulation of DNA damage repair, making it a compelling therapeutic target for the treatment of many cancer indications. A number of ATR inhibitors have been developed to date and have shown promising effects on solid tumors, both as monotherapies and as combination therapies with chemotherapy, radiotherapy, and immunotherapy. ATR inhibitors that are currently in clinical development demonstrate low penetrance through the blood-brain barrier (BBB) into the central nervous system (CNS), making them sub-optimal therapeutic options for targeting tumors and metastases in the brain. Discovery and development of novel potent, CNS-penetrating selective ATR inhibitors could provide a new therapeutic approach for patients with brain tumors, who otherwise have very few treatment options. Here, we describe the use of the Enki™ platform, a generative artificial intelligence approach, to discover novel CNS-penetrating ATR inhibitors and our progress in the development of these inhibitors. The Enki™ platform utilizes generative AI and deep learning to search a broad chemical space to identify hits. It uses a latent diffusion model to optimize many properties simultaneously within the search space, including maximal potency against the primary target, selectivity, ADMET, and physicochemical properties. This platform was used to generate de novo molecules with optimized properties to penetrate the blood-brain barrier and specifically target ATR. The most promising of these molecules were synthesized. In vitro and in vivo data, including potency, selectivity, BBB permeability and metabolic stability for these compounds will be presented. Use of the Enki™ platform allows deeper exploration into chemical space and refinement of drug properties while also accelerating the drug development timeline. This has enabled our discovery of numerous ATR inhibitor candidates with selectivity and efficacy against ATR, as well as CNS-penetrance.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Bench or experimental · Consensus signal: Bench or experimental
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.003
Threshold uncertainty score0.009

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0010.000
Open science0.0010.000
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0030.002

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.037
GPT teacher head0.340
Teacher spread0.303 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designBench or experimental
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueNeuro-Oncology→Same topicPARP inhibition in cancer therapy→French-language works237,207→